IP Library Granted Patent US 7,205,151
Granted Patent B2
US 7,205,151 · App. 09/885,721 · Granted Apr 17, 2007

Complex mixtures exhibiting selective inhibition of cyclooxygenase-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,205,151
App. No.
09/885,721
Granted
Apr 17, 2007
Kind
B2
Abstract

A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.

Claims (7)

1. A composition comprising a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone, and an effective amount of at least one component selected from the group consisting of essential oils, fats and waxes, wherein said pharmaceutical grade extract provides 15 to 45 weight % of tetrahydroisohumulone of the composition.

2. The composition of claim 1 , further comprising a pharmaceutical acceptable carrier selected from the group consisting of coatings, isotonic and absorption delaying agents, binders and adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

3. The composition of claim 1 , further comprising a member selected from the group consisting of antioxidants, vitamins and minerals.

4. The composition of claim 1 , further comprising a member selected from the group consisting of proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and amino sugars.

5. A dosage form of a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone, and an effective amount of at least one component, selected from the group consisting of essential oils, fats, and waxes, wherein said pharmaceutical grade extract provides 15 to 45 weight % of tetrahydroisohumulone of the composition.

6. The dosage form of claim 5 , wherein said dosage form is a capsule, powder, tablet, injectable suspension, spray solution, spray suspension, or lotion.

7. The dosage form of claim 5 , further comprising a pharmaceutical acceptable carrier selected from the group consisting of coatings, isotonic and absorption delaying agents, binders and adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023419/0486 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →